Market Research Logo

Finding and Evaluating Oncology Opportunities at BIO Asia 2017- A 1stOncology Insights Report

Finding and Evaluating Oncology Opportunities at BIO Asia 2017- A 1stOncology Insights Report

This report is a unique resource for finding and evaluating oncology opportunities at the BIO Asia 2017 meeting and is a must read for anyone with an interest in oncology at this exclusive partnering forum.

This report features the oncology position and activities of 61 companies identified by the analyst team at 1stOncology™. This provides you with the ability to review partnering opportunities for close to 900, partnered or as yet un-partnered, drugs in 17 "hot" areas in oncology, including:

  • Most recent Positive/Negative Developments (226/43)
  • Start-Ups (4)
  • Fierce 15 Drugs (53)
  • Orphan Drugs (252)
  • Breakthrough Therapies (31)
  • Cancer Vaccines (59)
  • CAR/TCR Therapies (14)
  • Immune Checkpoints (67)
  • Epigentic Therapies (35)
  • Protein Kinase Inhibitors (194)
  • Antibodies in Oncology (345)
  • Cancer Peptides (47)
  • RNA Therapies (13)
  • Conjugated Drugs (109)
  • Biomarker/Companion Diagnostic Drugs (166)
  • Combination Therapy Drugs (492)
  • Biosimilars/Biobetters (27)
(Number of Drugs in Each Area)

Use this report to make sure you spend your time and resources around BIO Asia where it reaps the most value. Understand in advance from a trustworthy third-party the position of the companies you will meet, the strengths and weaknesses of their pipeline, their partnering position and their recent successes and failures. It includes almost one thousand references detailing the latest positive and negative pipeline development for circa 250 top cancer drugs throughout 2016 to present, giving you a comprehensive insight to current developments such as successful clinical trials, trials with missed primary endpoints, new or terminated partnerships, M&A and much more.

To further fuel your ability to actively drive forward your partnering activities, this special BIO Asia 2017 report in oncology also includes circa 300 contacts to business development and licensing people within the featured companies, allowing you to reach out quickly and directly to the right person of interest for initial introductions, partnership discussions, pre-booking meetings etc."


1 Executive Summary
2 About 1stOncology™ Insights
2.1 Scope and Methodology
3 Table of Contents
3.1 List of Figures
3.2 List of Tables
4 Cancer Companies Participating at BIO Asia 2017
5 Major Recent Developments on Cancer Drugs at BIO Asia from 2016 to Present
5.1 Positive Highlights On 226 Cancer Drugs by Highest Stage
5.1.1 Marketed
5.1.2 Pre-registration
5.1.3 Phase III
5.1.4 Phase II
5.1.5 Phase I
5.1.6 Preclinical
5.1.7 Discovery
5.2 Negative Highlights on 43 Cancer Drugs by Highest Stage
5.2.1 Marketed
5.2.2 Pre-registration
5.2.3 Phase III
5.2.4 Phase II
5.2.5 Phase I
6 The Cancer Pipeline of Start-ups
6.1 Partnering Opportunity Review by Company
6.2 Partnering Opportunity Review by Highest Stage
7 Fierce 15 Cancer Drugs
7.1 Partnering Opportunity Review by Company
7.2 Partnering Opportunity Review by Highest Stage
8 Orphan Drugs in Oncology
8.1 Partnering Opportunity Review by Company
8.2 Partnering Opportunity Review by Highest Stage
9 Breakthrough Therapies in Oncology
9.1 Partnering Opportunity Review by Company
9.2 Partnering Opportunity Review by Highest Stage
10 The Immuno-Oncology Pipeline
10.1 Cancer Vaccines
10.1.1 Partnering Opportunity Review by Company
10.1.2 Partnering Opportunity Review by Highest Stage
10.2 CAR/TCR Therapies
10.2.1 Partnering Opportunity Review by Company
10.2.2 Partnering Opportunity Review by Highest Stage
10.3 Immune Checkpoints
10.3.1 Partnering Opportunity Review by Company
10.3.2 Partnering Opportunity Review by Highest Stage
11 Epigenetic Therapies in Oncology
11.1 Partnering Opportunity Review by Company
11.2 Partnering Opportunity Review by Highest Stage
12 Protein Kinase Inhibitors in Oncology
12.1 Partnering Opportunity Review by Company
12.2 Partnering Opportunity Review by Highest Stage
13 Antibodies in Oncology
13.1 Partnering Opportunity Review by Company
13.2 Partnering Opportunity Review by Highest Stage
14 Cancer Peptides
14.1 Partnering Opportunity Review by Company
14.2 Partnering Opportunity Review by Highest Stage
15 RNA (miRNA, RNAi & siRNA) Therapies in Oncology
15.1 Partnering Opportunity Review by Company
15.2 Partnering Opportunity Review by Highest Stage
16 Conjugated Cancer Drugs
16.1 Partnering Opportunity Review by Company
16.2 Partnering Opportunity Review by Highest Stage
17 Cancer Drugs with Biomarker/Companion Diagnostic Development
17.1 Partnering Opportunity Review by Company
17.2 Partnering Opportunity Review by Highest Stage
18 Cancer Drugs in Combination Therapies
18.1 Partnering Opportunity Review by Company
18.2 Partnering Opportunity Review by Highest Stage
19 Biosimilars and Biobetters in Oncology
19.1 Partnering Opportunity Review by Company
19.2 Partnering Opportunity Review by Highest Stage
20 BD & Licensing Contacts
20.1 A*STAR
20.2 Abbvie
20.3 Ajinomoto
20.4 Aldevron
20.5 Anaeropharma Science
20.6 Anavex Life Sciences
20.7 Aptose Biosciences
20.8 Argen-X
20.9 Astellas Pharma
20.10 Bayer
20.11 BeyondSpring Pharmaceuticals
20.12 BioLeaders
20.13 BioLite
20.14 Boehringer Ingelheim
20.15 Capella Therapeutics
20.16 Chugai Pharmaceutical
20.17 CStone Pharmaceuticals
20.18 Cue Biopharma
20.19 Daiichi Sankyo
20.20 EMD Serono
20.21 EpiVax
20.22 Experimental Therapeutics Centre
20.23 GlaxoSmithKline
20.24 Glycostem Therapeutics
20.25 Golden Biotechnology
20.26 Intellia Therapeutics
20.27 Interprotein Corporation
20.28 Johnsson and Johnsson Innovation
20.29 Kaken Pharmaceutical
20.30 KISSEI Pharmaceutical
20.31 Kyowa Hakko Kirin
20.32 Leo Pharma
20.33 Ligand Pharmaceuticals
20.34 Maruho
20.35 Medigen Biotechnology
20.36 Mirati Therapeutics
20.37 Mitsubishi Tanabe Pharma
20.38 Mochida Pharmaceutical
20.39 Merck Sharp & Dohme
20.40 Mundipharma International
20.41 Nippon Kayaku
20.42 Northwestern University
20.43 OncoSec Medical
20.44 Ono Pharmaceutical
20.45 Opsona Therapeutics
20.46 Pfizer
20.47 PharmaEngine
20.48 Pierre Fabre Medicament
20.49 Prestige BioPharma
20.50 Roivant Sciences
20.51 Samyang Biopharmaceuticals
20.52 Sanofi
20.53 Sanwa Kagaku Kenkyusho
20.54 Servier
20.55 Spectrum Pharmaceuticals
20.56 TaiRx
20.57 Taisho Pharmaceutical
20.58 TENEObio
20.59 The University of Auckland Innovation Institute
20.60 Tracon Pharmaceuticals
20.61 Zai Lab
21 Disclaimer
22 Drug Index
23 Company Index
1.1 List of Figures
Figure 1: Distribution of Start-up Drugs in Oncology by Highest Stage of Development
Figure 2: Distribution of Fierce 15 Drugs in Oncology by Highest Stage of Development
Figure 3: Distribution of Orphan Drugs in Oncology by Highest Stage of Development
Figure 4: Distribution of Breakthrough Therapy Drugs in Oncology by Highest Stage of Development
Figure 5: Distribution of Cancer Vaccine Drugs by Highest Stage of Development
Figure 6: Distribution of CAR/TCR Therapy Drugs in Oncology by Highest Stage of Development
Figure 7: Distribution of Immune Checkpoint Drugs in Oncology by Highest Stage of Development
Figure 8: Distribution of Epigenetic Therapy Drugs in Oncology by Highest Stage of Development
Figure 9: Distribution of Protein Kinase Inhibitors in Oncology by Highest Stage of Development
Figure 10: Distribution of Antibody Drugs in Oncology by Highest Stage of Development
Figure 11: Distribution of Peptide Drugs in Oncology by Highest Stage of Development
Figure 12: Distribution of RNA (miRNA, RNAi & siRNA) Drugs in Oncology by Highest Stage of Development
Figure 13: Distribution of Conjugated Drugs in Oncology by Highest Stage of Development
Figure 14: Distribution of Cancer Drugs with Biomarke/Companion Diagnostic Development by Highest Stage of Development
Figure 15: Distribution of Cancer Drugs in Combination Therapies by Highest Stage of Development
Figure 16: Distribution of Biosimilars and Biobetters in Oncology by Highest Stage of Development
1.2 List of Tables
Table 1: List of Participating Oncology Companies at BIO Asia 2017
Table 2: Partnering Opportunity Review on Four Drugs in Oncology of Start-ups by Company
Table 3: Partnering Opportunity Review on Four Drugs in Oncology of Start-up by Highest Stage of Development
Table 4: Partnering Opportunity Review on 53 Fierce 15 Cancer Drugs by Company
Table 5: Partnering Opportunity Review on 53 Fierce 15 Cancer Drugs by Highest Stage of Development
Table 6: Partnering Opportunity Review on 252 Orphan Drugs in Oncology by Company
Table 7: Partnering Opportunity Review on 252 Orphan Drugs in Oncology by Highest Stage of Development
Table 8: Partnering Opportunity Review on 31 Breakthrough Therapy Drugs in Oncology by Company
Table 9: Partnering Opportunity Review on 31 Breakthrough Therapy Drugs in Oncology by Highest Stage of Development
Table 10: Partnering Opportunity Review on 59 Cancer Vaccine Drugs by Company
Table 11: Partnering Opportunity Review on 59 Cancer Vaccine Drugs by Highest Stage of Development
Table 12: Partnering Opportunity Review on 14 CAR/TCR Therapy Drugs in Oncology by Company
Table 13: Partnering Opportunity Review on 14 CAR/TCR Therapy Drugs in Oncology by Highest Stage of Development
Table 14: Partnering Opportunity Review on 67 Immune Checkpoint Drugs in Oncology by Company
Table 15: Partnering Opportunity Review on 67 Immune Checkpoint Drugs in Oncology by Highest Stage of Development
Table 16: Partnering Opportunity Review on 35 Epigenetic Therapy Drugs in Oncology by Company
Table 17: Partnering Opportunity Review on 35 Epigenetic Therapy Drugs in Oncology by Highest Stage of Development
Table 18: Partnering Opportunity Review on 194 Protein Kinase Inhibitors in Oncology by Company
Table 19: Partnering Opportunity Review on 194 Protein Kinase Inhibitors in Oncology by Highest Stage of Development
Table 20: Partnering Opportunity Review on 345 Antibodies in Oncology by Company
Table 21: Partnering Opportunity Review on 345 Antibodies in Oncology by Highest Stage of Development
Table 22: Partnering Opportunity Review on 47 Peptide Drugs in Oncology by Company
Table 23: Partnering Opportunity Review on 47 Peptide Drugs in Oncology by Highest Stage of Development
Table 24: Partnering Opportunity Review on 13 RNA-(miRNA, RNAi & siRNA) in Oncology by Company
Table 25: Partnering Opportunity Review on 13 RNA-(miRNA, RNAi & siRNA) in Oncology by Highest Developmental Stage
Table 26: Partnering Opportunity Review on 109 Conjugated Drugs in Oncology by Company
Table 27: Partnering Opportunity Review on 109 Conjugated Drugs in Oncology by Highest Stage of Development
Table 28: Partnering Opportunity Review on 166 Cancer Drugs with Biomarker/Companion Diagnostic Development by Company
Table 29: Partnering Opportunity Review on 166 Cancer Drugs with Biomarker/Companion Diagnostic Development by Highest Stage of Development
Table 30: Partnering Opportunity Review on 492 Combination Therapy Drugs in Oncology by Company
Table 31: Partnering Opportunity Review on 492 Combination Therapy Drugs in Oncology by Highest Stage of Development
Table 32: Partnering Opportunity Review on 27 Biosimilar/Biobetter Drugs in Oncology by Company
Table 33: Partnering Opportunity Review on 27 Biosimilar/Biobetter Drugs in Oncology by Highest Stage of Development

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report